AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025.

Preliminary, unaudited revenue for fourth quarter 2024 is expected to be $124.3 million, reflecting growth of approximately 17% as reported and on a constant currency basis over the fourth quarter of 2023. U.S. revenue is expected to be $101.6 million, reflecting growth of approximately 14%, and international revenue is expected to be $22.7 million, an increase of approximately 28% as reported and on a constant currency basis. Fourth quarter revenue was driven by strong growth in our cryoSPHERE® devices for pain management, AtriClip® devices in open chest procedures, and the EnCompass® clamp.

Preliminary, unaudited revenue for full year 2024 is expected to be $465.3 million, reflecting growth of approximately 17% as reported and on a constant currency basis over full year 2023. As previously communicated, management expects full year 2024 positive adjusted EBITDA of approximately $26 million to $29 million, and full year 2024 adjusted loss per share of approximately $0.74 to $0.80. Adjusted EBITDA, adjusted loss per share and constant currency revenue growth are non-GAAP measures. AtriCure will provide a reconciliation of non-GAAP measures to the related GAAP measure in the release of audited 2024 results. Management will discuss financial results on the fourth quarter and full year 2024 conference call in February.